Hyperuricemia (Metabolic Disorder) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Drugs In Development, 2021, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Allena Pharmaceuticals Inc

Arthrosi Therapeutics Inc

AstraZeneca Plc

FortuneRock (China) Ltd

Fuji Yakuhin Co Ltd

Hangzhou Grand Biologic Pharmaceutical Inc

Hinova Pharmaceuticals Inc

InventisBio Inc

J-Pharma Co Ltd

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

NuBioPharma LLC

PegBio Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Yingli Pharmaceutical Co Ltd

Shanton Pharma Co Ltd

Stealth Biologics LLC

Suzhou Sinovent Pharmaceuticals Co Ltd

Teijin Pharma Ltd

Xiuzheng Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperuricemia - Overview

Hyperuricemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperuricemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperuricemia - Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

Arthrosi Therapeutics Inc

AstraZeneca Plc

FortuneRock (China) Ltd

Fuji Yakuhin Co Ltd

Hangzhou Grand Biologic Pharmaceutical Inc

Hinova Pharmaceuticals Inc

InventisBio Inc

J-Pharma Co Ltd

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

NuBioPharma LLC

PegBio Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Yingli Pharmaceutical Co Ltd

Shanton Pharma Co Ltd

Stealth Biologics LLC

Suzhou Sinovent Pharmaceuticals Co Ltd

Teijin Pharma Ltd

Xiuzheng Pharmaceutical Group Co Ltd

Hyperuricemia - Drug Profiles

(allopurinol +verinurad) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABP-671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLN-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

allopurinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-882 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-0120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-501 SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HZBio-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPH-367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JS-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme for Gout and Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taininade - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topiroxostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verinurad - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XNW-3009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YL-90148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperuricemia - Dormant Projects

Hyperuricemia - Discontinued Products

Hyperuricemia - Product Development Milestones

Featured News & Press Releases

Jul 12, 2021: Allena Pharmaceuticals provides update on ALLN-346 clinical development program

Mar 05, 2021: Shanghai Junshi Bioscience announces JS103 Injection received the acceptance notice for the investigational new drug application

Nov 30, 2020: Allena Pharmaceuticals announces initial data from phase 1 trial of ALLN-346

Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of Hyperuricemia in patients with gout and advanced chronic kidney disease

Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019

Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting

Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease

Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)

Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial

Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results

Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346

Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting

Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study

Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hyperuricemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hyperuricemia – Pipeline by Allena Pharmaceuticals Inc, 2021

Hyperuricemia – Pipeline by Arthrosi Therapeutics Inc, 2021

Hyperuricemia – Pipeline by AstraZeneca Plc, 2021

Hyperuricemia – Pipeline by FortuneRock (China) Ltd, 2021

Hyperuricemia – Pipeline by Fuji Yakuhin Co Ltd, 2021

Hyperuricemia – Pipeline by Hangzhou Grand Biologic Pharmaceutical Inc, 2021

Hyperuricemia – Pipeline by Hinova Pharmaceuticals Inc, 2021

Hyperuricemia – Pipeline by InventisBio Inc, 2021

Hyperuricemia – Pipeline by J-Pharma Co Ltd, 2021

Hyperuricemia – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2021

Hyperuricemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Hyperuricemia – Pipeline by Nippon Chemiphar Co Ltd, 2021

Hyperuricemia – Pipeline by NuBioPharma LLC, 2021

Hyperuricemia – Pipeline by PegBio Co Ltd, 2021

Hyperuricemia – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021

Hyperuricemia – Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, 2021

Hyperuricemia – Pipeline by Shanton Pharma Co Ltd, 2021

Hyperuricemia – Pipeline by Stealth Biologics LLC, 2021

Hyperuricemia – Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, 2021

Hyperuricemia – Pipeline by Teijin Pharma Ltd, 2021

Hyperuricemia – Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, 2021

Hyperuricemia – Dormant Projects, 2021

Hyperuricemia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hyperuricemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports